Bacterial Vaginosis: Clinical Trials

32 trials for Bacterial Vaginosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 8 unknown, 2 not yet recruiting, 2 terminated. 32 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 332Completed 20, Unknown 8, Not yet recruiting 2, Terminated 2
Phase 26Completed 3, Unknown 2, Not yet recruiting 1

Follow Bacterial Vaginosis: new trials by email Literature Review of Bacterial Vaginosis trials Research Report on Bacterial Vaginosis

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth
Vaginal flora abnormalities screening and quantification using molecular biology technique, Azithromycin, Ceftriaxone - Bacterial Vaginosis, Vaginal Dysbiosis
Phase 3Not yet recruitingAssistance Publique Hopitaux De Marseille17942026-10-012026-08-27
Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis
Lactobacillus gasseri KABP®064 10e9 CFU/capsule, Placebo (maltodextrin) - Vaginosis, Bacterial, Bacterial Vaginosis
Phase 2 / Phase 3Not yet recruitingKaneka Americas Holding Inc.1602026-04-012026-04-14
Effect of PreforPro® on Urinary and Vaginal Health
Preforpro, Placebo - Bacterial Vaginosis, Bacterial Infections
Phase 3UnknownJeremy Burton502024-05-012024-01-09
Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule
EVEGYN A, EVEGYN B, Gynomax® XL Vaginal Ovule - Trichomonal Vaginitis, Bacterial Vaginosis
Phase 3CompletedEge University5772020-07-202023-09-28
DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)
DARE-BV1clindamycin phosphate vaginal gel, 2% - Bacterial Vaginosis
Phase 3CompletedDaré Bioscience, Inc.3072020-06-162022-12-08
Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo - Bacterial Vaginosis
Phase 3CompletedBalmoral Medical company8712017-03-102020-01-07
Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections
Association of metronidazole; nystatin and dexamethasone, Flagyl - Bacterial Vaginosis, Fungal Vaginal Infections
Phase 3UnknownMarjan Industria e Comercio ltda1602016-01-012015-04-09
Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219
SYM-1219 - Bacterial Vaginosis
Phase 3CompletedSymbiomix Therapeutics3252015-06-012021-04-13
A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
SYM-1219, Placebo - Bacterial Vaginosis
Phase 3CompletedSymbiomix Therapeutics1892015-05-282021-10-15
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel - Bacterial Vaginosis
Phase 3CompletedStarpharma Pty Ltd5862014-10-132019-07-22
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel - Bacterial Vaginosis
Phase 3CompletedStarpharma Pty Ltd6372014-10-032018-06-25
Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis
Gynevac, Placebo - Bacterial Vaginosis
Phase 3UnknownAmvac Kft.2402014-06-012014-10-29
BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study
Placebo, Boric acid, Metronidazole - Bacterial Vaginosis
Phase 2 / Phase 3CompletedUniversity of British Columbia132014-04-012016-10-27
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
clindamycin phosphate vaginal cream 2%, placebo - BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include
Phase 3CompletedActavis Inc.6042014-01-012020-01-28
Safety and Efficacy Study to Treat Bacterial Vaginosis
Product 55394, Placebo Vehicle (non-treatment) - Bacterial Vaginosis
Phase 3CompletedMedicis Global Service Corporation6512012-05-012013-08-21
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
1% SPL7013 Gel, Placebo - Bacterial Vaginosis
Phase 3CompletedStarpharma Pty Ltd2512012-04-172019-07-17
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
1% SPL7013 Gel, Placebo - Bacterial Vaginosis
Phase 3CompletedStarpharma Pty Ltd2502012-03-282019-07-17
A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis
Lactofiltrum + Metronidazole, Metronidazole - Bacterial Vaginosis
Phase 2 / Phase 3UnknownAvva Rus, JSC902010-07-012010-07-21
Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery
VA-SENSE - Vaginal Infections, Bacterial Vaginosis
Phase 3UnknownCommon Sense2482010-07-012010-06-29
The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis
Yogurt supplemented with L. rhamnosus fiti, Yogurt not supplemented with a probiotic strain. - Bacterial Vaginosis
Phase 2 / Phase 3CompletedLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's1502010-06-012010-12-13

Showing 20 of 32. Sign in to see all of them.

Narrower conditions

Vaginosis, Bacterial (32)  ·  Vaginitis (4)  ·  Premature Birth (3)  ·  Candidiasis (2)  ·  Candidiasis, Vulvovaginal (2)  ·  Chlamydia Infections (2)  ·  Gonorrhea (2)  ·  HIV Infections (2)  ·  Trichomonas Vaginitis (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Bacterial Infections (1)  ·  Bronchopulmonary Dysplasia (1)  ·  Communicable Diseases (1)  ·  Diarrhea (1)  ·  Herpes Genitalis (1)

Broader conditions

Bacterial Infections and Mycoses (32)  ·  Female Urogenital Diseases (32)  ·  Female Urogenital Diseases and Pregnancy Complications (32)  ·  Genital Diseases (32)  ·  Genital Diseases, Female (32)  ·  Infections (32)  ·  Bacterial Infections (31)  ·  Urogenital Diseases (31)  ·  Vaginal Diseases (31)  ·  Vaginitis (28)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Disease Attributes (3)  ·  Immune System Diseases (3)  ·  Mycoses (3)

Interventions

Metronidazole (8)  ·  astodrimer (4)  ·  Clindamycin (2)  ·  Amphotericin B (1)  ·  Azithromycin (1)  ·  Ceftriaxone (1)  ·  Circumcision, Male (1)  ·  Clotrimazole (1)  ·  Dequalinium (1)  ·  Dexamethasone (1)  ·  Doxycycline (1)  ·  Ketoconazole (1)  ·  Nystatin (1)  ·  Tetracycline (1)  ·  Tinidazole (1)

Sponsors

Starpharma Pty Ltd (4)  ·  Symbiomix Therapeutics (2)  ·  Actavis Inc. (1)  ·  Amvac Kft. (1)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  Avva Rus, JSC (1)  ·  Balmoral Medical company (1)  ·  Common Sense (1)  ·  Daré Bioscience, Inc. (1)  ·  Ege University (1)  ·  Embil Pharmaceutical Co. Ltd (1)  ·  Jeremy Burton (1)  ·  Johns Hopkins Bloomberg School of Public Health (1)  ·  Kaneka Americas Holding Inc. (1)  ·  Laboratoires Lyocentre (1)

Countries

United States (11)  ·  Brazil (3)  ·  Canada (2)  ·  Czechia (2)  ·  Hungary (2)  ·  Puerto Rico (2)  ·  Tanzania (2)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Dominican Republic (1)  ·  France (1)  ·  Germany (1)  ·  Ghana (1)  ·  Guinea (1)  ·  Israel (1)

Top investigators

Jeremy Paull, PhD (2)  ·  Jeremy Paull, PhD. (2)  ·  David Serwadda, MBChB,MPH (1)  ·  Ernst Rainer Weissenbacher, MD (1)  ·  Godfrey Kigozi, MBChB, MPH (1)  ·  Jacques Pepin, MD (1)  ·  Jermy Burton (1)  ·  John Changalucha, MSc (1)  ·  Kate V Meriwether, MD (1)  ·  Konia Trouton, MD (1)  ·  Leticia Krauss-Silva, MD, Ph.D (1)  ·  Lyudmila Kobeleva, MD, PhD (1)  ·  Melinda Zeron Mullins, MD, Ph.D (1)  ·  Nicodemus Butamanya, MD (1)

Results publications

PMID 17128343, PMID 17666604, PMID 18532873, PMID 19220138, PMID 19321868, PMID 19389002, PMID 19616720, PMID 19936044, PMID 20370481, PMID 20591191, PMID 20801446, PMID 21216000, PMID 21489882, PMID 22059409, PMID 22205034, PMID 25935783, PMID 26210791, PMID 26611782, PMID 29474292, PMID 30002871, PMID 30807423, PMID 33207004, PMID 35675606, PMID 37098453

NIH funding

2023 (1)